REFERENCES
- Johnson P E. Legal and practice concerns with extemporaneously compounded medications. J Pharm Care Pain Sympt Control 1997; 5(3)47–57
- Allen L V. Extemporaneous compounding in the 1990s. U.S. Pharmacist 1989; 14(Dec)58–64
- Rusho W J. Clinical issues and concerns in the use of extemporaneously compounded medications. J Pharm Care Pain Sympt Control 1996; 4(4)5–20
- Dow Chemical Company. Formulating for controlled release with Methocel Premium cellulose ethers. Dow Chemical Company, Midland, MI 1995
- The United States Pharmacopeia, 23rd ed. United Sates Pharmacopeial Convention, Inc, Rockville, MS 1995
- Buri P P, Doelker E. Formulation des comprimés à libération prolongée ii, matrices hydrophiles. Pharm Acta Helv 1980; 55: 189–97
- Alderman D A. A review of cellulose ethers in hydrophilic matrices for oral controlled-release dosage forms. Int J Pharm Tech, & Prod Mfr 1984; 5(3)1–9
- Dow Chemical Company. Methocel Cellulose Ethers Technical Handbook. Dow Chemical Company, Midland, MI 1996
- Reich I, Sugita E T, Schnaare R L. Metrology and calculations. Remington: The Science and Practice of Pharmacy, 19th ed, A R Gennaro. Mack Publishing Co, Easton, PA 1995
- National Association of Boards of Pharmacy. NABP guidelines: good compounding practices applicable to state-licensed pharmacies. Int J Pharmaceut Compounding 1997; 1: 75–7